Background: ARDS mortality is still high, many biomarkers had been used to predict the mortality but they may have many drawbacks because of its validity, complications and cost.Study design: Observational study was planned to evaluate the predictive role of serum uric acid level in ARDS outcome. Mortality was the primary end-point while secondary endpoints included total ICU stay, duration of mechanical ventilation and the presence or absence of complications.Aim: The aim of this work is to study the role of serum uric acid level as an outcome predictor in ARDS patients.Patients and methods: Thirty three ARDS patients were enrolled in this study according to Berlin 2012 definition. Patients with diabetes mellitus, chronic renal failure, cardiovascular disorders, decompensated liver disease and known malignancies were excluded from the study. On admission to ICU serum uric acid level was investigated.Results: Sensitivity and specificity of uric acid as an outcome predictor at a cut off of 8.4 mg/dl were 89% and 80% respectively; the area under curve was 0.88 with p value <0.001, mortality in a high uric acid group that reported to be 86.7% was statistically significant higher than the normal uric acid group 38.9%. Conclusion: Serum uric acid level at 8.4 mg/dl cut off point predicts mortality in ARDS patients with 89% sensitivity and 80% specificity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.